Axel Nordström

Axel Nordström

Auto-generated profile, based on publicly available information

Axel Nordström

Department of Health Promotion Science Sophiahemmet University Stockholm Sweden

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
TKTobias Karlberg
Tobias Karlberg
PHPeter Hornyak
Peter Hornyak
APAna Filipa Pinto
Ana Filipa Pinto
SMStefina Milanova
Stefina Milanova
MEMahsa Ebrahimi
Mahsa Ebrahimi
HSHerwig Schüler
Herwig Schüler
Pseudomonas are a common cause of hospital-acquired infections that may be lethal. ADP-ribosyltransferase activities of Pseudomonas exotoxin-S and -T depend on 14-3-3 proteins inside the host cell. By binding in the 14-3-3 phosphopeptide binding groove, an amphipathic C-terminal helix of ExoS and ExoT has been thought to be crucial for their activation. However, crystal structures of the 14-3-3β:ExoS and -ExoT complexes presented here reveal an extensive hydrophobic interface that is sufficient for complex formation and toxin activation. We show that C-terminally truncated ExoS ADP-ribosyltransferase domain lacking the amphipathic binding motif is active when co-expressed with 14-3-3. Moreover, swapping the amphipathic C-terminus with a fragment from Vibrio Vis toxin creates a 14-3-3 independent toxin that ADP-ribosylates known ExoS targets. Finally, we show that 14-3-3 stabilizes ExoS against thermal aggregation. Together, this indicates that 14-3-3 proteins activate exotoxin ADP-ribosyltransferase domains by chaperoning their hydrophobic surfaces independently of the amphipathic C-terminal segment.

23 July 2022 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Open access
ANAxel Nordström
Axel Nordström
MJMattias Jangard
Mattias Jangard
MSMarie Svedberg
Marie Svedberg
MRMichael Ryott
Michael Ryott
MKMaria Kumlin
Maria Kumlin
Severe nasal polyposis and mucosal inflammation, in patients with chronic rhinosinusitis (CRS) may include a dysregulated eicosanoid profile, but a clinical role for eicosanoids in CRS with nasal polyps (NP; CRSwNP) remains to be elucidated. This study focused on assessing levels and clinical implications of inflammatory mediators in nasal secretions and urine from patients with different NP severity or Aspirin Exacerbated Respiratory Disease (AERD). Levels of leukotrienes E4 and B4, prostaglandins D2 and E2 as well as 15(S)-hydroxyeicosatetraenoic acid were measured with enzyme immunoassays and cytokines with magnetic bead immunoassays. Patients with CRSwNP were subdivided based on NP score; CRSwNP-low (NP score ≤ 4, n = 11) or CRSwNP-high (NP score ≥ 5, n = 32) and compared to CRS without polyps (CRSsNP, n = 12), CRSwNP-AERD (n = 11) and individuals without CRS (n = 25). Smell test score, fractional exhaled nitric oxide (FeNO), blood eosinophils and Sinonasal outcome test-22 were assessed as clinical markers. Leukotriene E4, prostaglandin D2 and 15(S)-hydroxyeicosatetraenoic acid in nasal secretions correlated with NP score. Nasal leukotriene E4 also correlated with FeNO and smell test score, with highest levels found in CRSwNP-AERD. Levels of prostaglandin D2 in nasal secretion as well as urinary levels of the prostaglandin D2 metabolite 11β-prostaglandin F2α differed between CRSNP-high and CRSwNP-low. Urinary 11β-prostaglandin F2α was associated with asthma comorbidity whereas a similar association with prostaglandin D2 in nasal secretions was not observed. In conclusion, subdividing patients based on NP severity in combination with analysis of eicosanoids in non-invasively collected nasal secretions, may have clinical implications when assessing CRS disease severity.

10 November 2021 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
PDF file
ANAxel Nordström
Axel Nordström
MJMattias Jangard
Mattias Jangard
MSMarie Svedberg
Marie Svedberg
HKHelena Kullenberg
Helena Kullenberg
MRMichael Ryott
Michael Ryott
MKMaria Kumlin
Maria Kumlin
Objectives Previous studies have shown that hot saline solution (HSS) nasal irrigation is effective against nasal bleeding and is used to treat nasal hemorrhage. In a pilot study, we evaluated hot saline nasal irrigation in comparison to a routinely used nasal packing in terms of self-reported complications and mucosal healing after functional endoscopic sinus surgery. Methods Patients undergoing surgery for bilateral chronic rhinosinusitis received polyvinyl acetate (PVA) nasal packing in the left nostril, and the right nostril was rinsed with 47°C sterile saline immediately after surgery. Patients' experiences of pain, bleeding, and other types of uncomfortable experiences were measured using a visual analog scale for each nostril before, during, and immediately after nasal packing removal. Two weeks post-surgery, the assessments were repeated including an endoscopic evaluation of the mucosa by the surgeon. Results Twenty-seven patients completed the study. Prior to removal of the packing, the patients experienced significantly more pain and other uncomfortable experiences in the nostril treated with nasal packing, as compared to the nostril solely rinsed with hot saline. After removal, patients reported significantly more uncomfortable experiences from the packing treated nostril. Two weeks post-surgery, no difference in mucosal healing was observed between the two nostrils. Conclusions The results from this study indicate that irrigation with HSS could be an alternative postoperative treatment to conventional PVA nasal packing. Hot saline irrigation may contribute to patients experiencing improved control of postoperative bleeding, pain, and less suffering of other causes as well as health-economic benefits, without affecting the mucosal healing up to 2 weeks post-surgery. Level of Evidence 1b

28 May 2023 in International Forum of Allergy & Rhinology
Verified
Journal Article
Open access
ANAxel Nordström
Axel Nordström
MJMattias Jangard
Mattias Jangard
MSMarie Svedberg
Marie Svedberg
MRMichael Ryott
Michael Ryott
MKMaria Kumlin
Maria Kumlin
Background: Although altered eicosanoid levels are related to disease severity in chronic rhinosinusitis with nasal polyps (CRSwNP), identifying patients prone to recurrent nasal polyps (NPs) is still difficult. We investigated levels of nasally secreted eicosanoids before and after NP surgery in patients with or without NP recurrence (NPR) and explored potential endotypes based on pre‐surgical eicosanoid levels.Methods: Levels of leukotriene (LT) E4, LTB4, prostaglandin (PG) D2, PGE2 and 15(S) hydroxyeicosatetraenoic acid (15[S]‐HETE) were measured in nasal secretions with specific immunoassays at pre‐surgery (n = 38) and 6 and 12 months post‐surgery (n = 35), with NPR identified endoscopically. Pre‐ and post‐surgical levels were compared between patients with and without NPR. Eicosanoid patterns among patients were explored with cluster analysis and evaluated with clinical parameters.Results: Patients with recurrent NPs had pronounced pre‐surgical levels of nasal 15(S)‐HETE, PGD2 and LTE4. From pre‐surgery to 12 months post‐surgery, NPR was associated with significant decreases of 15(S)‐HETE and PGD2 relative to non‐recurrence, whereas levels of LTE4 decreased at 6 months but increased again at 12 months. Clustering revealed three potential endotypes. Clusters 1 and 3 featured high and low eicosanoid levels, respectively. Cluster 2 had higher levels of LTE4 and PGD2, lower levels of PGE2 and LTB4, and more cases of recurrent NPs and previous NP surgeries.Conclusion: Elevated nasal LTE4 12 months post‐surgery in NP recurrent subjects suggests that postoperative LTE4 measurements may indicate rapid NP regrowth. A distinct nasal eicosanoid profile may be used for the identification of the most severe recalcitrant patients in need of targeted immunomodulatory therapies.

10 March 2022
Verified
Conference Paper
Closed access
ANAxel Nordström
Axel Nordström
MJMattias Jangard
Mattias Jangard
MSMarie Svedberg
Marie Svedberg
MRMichael Ryott
Michael Ryott
MKMaria Kumlin
Maria Kumlin
Objective: To identify easily accessible biomarkers for mucosal inflammation and disease progression in chronic rhinosinusitis (CRS) we assessed levels of inflammatory mediators in nasal secretions and urine related to nasal polyp (NP) severity or Aspirin Exacerbated Respiratory Disease (AERD). Methods: Samples were collected from patients with CRS without NP (CRSsNP) or with (CRSwNP) and/or AERD and controls. CRSwNP was further subdivided based on nasal polyp scores; NP-low (NPS≤4) or NP-high (NPS≥5). Nasal secretion and urine samples were analyzed for lipid mediators and cytokines. Mediator levels were compared between subgroups and correlated to clinical parameters as exhaled nitric oxide (FeNO), blood eosinophil counts and smell test score. Results: Nasal secretions from patients with CRSwNP-AERD had elevated levels of LTE4, resolvin (Rv)D1 and IL-6 and NP-high had increased levels of PGD2, both in comparison to NP-low. Cytokines featured generally low detection in nasal secretions, although IL-13 was exclusively detectable in NP-high and CRSwNP-AERD. The PGD2 metabolite 11β-PGF2α was elevated in urine from NP-high and CRSwNP-AERD as opposed to CRSsNP and correlated with smell test score. Nasal LTE4 and RvD1 was correlated to lowered smell test score as well as to elevated FeNO. Conclusion: Patients with different nasal polyp severity and /or AERD may be distinguished by altered levels of lipid mediators in nasal mucosa in readily available and non-invasively collected nasal secretions, and changes in lipid mediator levels seems related to the degree of smell loss and FeNO.